- Home
- SAGE vs UHT Comparison
SAGE vs UHT Comparison
Compare SAGE & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- UHT
- Stock Information
- Founded
- SAGE 2010
- UHT 1986
- Country
- SAGE United States
- UHT United States
- Employees
- SAGE N/A
- UHT N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- UHT Real Estate Investment Trusts
- Sector
- SAGE Health Care
- UHT Real Estate
- Exchange
- SAGE Nasdaq
- UHT Nasdaq
- Market Cap
- SAGE 571.7M
- UHT 557.7M
- IPO Year
- SAGE 2014
- UHT N/A
- Fundamental
- Price
- SAGE $9.08
- UHT $41.21
- Analyst Decision
- SAGE Hold
- UHT
- Analyst Count
- SAGE 18
- UHT 0
- Target Price
- SAGE $10.06
- UHT N/A
- AVG Volume (30 Days)
- SAGE 2.8M
- UHT 66.8K
- Earning Date
- SAGE 07-30-2025
- UHT 07-23-2025
- Dividend Yield
- SAGE N/A
- UHT 7.16%
- EPS Growth
- SAGE N/A
- UHT 15.38
- EPS
- SAGE N/A
- UHT 1.35
- Revenue
- SAGE $47,404,000.00
- UHT $99,725,000.00
- Revenue This Year
- SAGE $102.21
- UHT $3.87
- Revenue Next Year
- SAGE $43.01
- UHT $3.97
- P/E Ratio
- SAGE N/A
- UHT $30.02
- Revenue Growth
- SAGE N/A
- UHT 1.03
- 52 Week Low
- SAGE $4.62
- UHT $34.56
- 52 Week High
- SAGE $13.47
- UHT $47.30
- Technical
- Relative Strength Index (RSI)
- SAGE 71.54
- UHT 58.91
- Support Level
- SAGE $9.04
- UHT $39.40
- Resistance Level
- SAGE $9.30
- UHT $40.72
- Average True Range (ATR)
- SAGE 0.15
- UHT 0.85
- MACD
- SAGE 0.05
- UHT -0.07
- Stochastic Oscillator
- SAGE 91.35
- UHT 70.98
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.